Itoco (Dorzolamide Hydrochloride)

Dorzolamide Hydrochloride blocks carbonic anhydrase enzymes in the ciliary body, decreasing bicarbonate formation that drives aqueous humor secretion. This reduction in fluid production lowers intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and related pressure‑elevating eye conditions.

The specific dosing regimen for Itoco is determined by the prescribing ophthalmologist based on the patient’s condition, severity, and response to therapy. Typically, the medication is administered as one or two drops per eye daily, but exact frequency and duration must follow the prescriber’s instructions.

Safety data for Dorzolamide Hydrochloride in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss individual risk factors and consider alternative treatments when appropriate.

To request Itoco, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Itoco (Dorzolamide) is a carbonic anhydrase inhibitor, differing from prostaglandin analogues, beta‑blockers, or alpha‑agonists in its mechanism of reducing aqueous humor production. It can be used alone or in combination with other classes to achieve additive IOP reduction, offering flexibility for patients who need multi‑modal therapy.

Itoco should be stored at room temperature, preferably below 25 °C, in its original container. Protect the bottle from direct sunlight and moisture. Keep the solution tightly capped when not in use and discard any product that appears discolored or contaminated.

Itoco is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac. Contact lenses should be removed before instillation and reinserted after waiting a few minutes to avoid drug absorption issues.

Serious adverse events, though rare, include severe allergic reactions such as angio‑edema or anaphylaxis, corneal edema or keratitis that can impair vision, and persistent intra‑ocular inflammation. Patients should seek immediate medical attention if they experience sudden vision loss, intense eye pain, or signs of systemic allergy.

Itoco is contraindicated in individuals with a known hypersensitivity to Dorzolamide, sulfonamides, or any component of the formulation. Patients with severe sulfonamide allergy, active ocular infections, or those who cannot safely remove contact lenses before dosing should avoid using this product.